Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.

Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH.

PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May.

2.

IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.

Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF.

Hepatology. 2019 May 7. doi: 10.1002/hep.30699. [Epub ahead of print]

PMID:
31062385
3.

Learning from a clinical cohort for HCV vaccine development.

Wrensch F, Keck ZY, Foung SKH, Baumert TF.

J Hepatol. 2019 Apr 13. pii: S0168-8278(19)30224-7. doi: 10.1016/j.jhep.2019.03.030. [Epub ahead of print] No abstract available.

PMID:
30992137
4.

Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.

Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, Ball JK, Pierce BG, Mariuzza RA, Foung SKH, Fuerst TR.

J Virol. 2019 Mar 21;93(7). pii: e01403-18. doi: 10.1128/JVI.01403-18. Print 2019 Apr 1.

5.

In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.

Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF.

Antiviral Res. 2019 Feb;162:136-141. doi: 10.1016/j.antiviral.2018.12.018. Epub 2018 Dec 30.

PMID:
30599173
6.

Isolation of HCV Neutralizing Antibodies by Yeast Display.

Keck ZY, Wang Y, Lau P, Foung SKH.

Methods Mol Biol. 2019;1911:395-419. doi: 10.1007/978-1-4939-8976-8_27.

7.

Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.

Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF.

Front Immunol. 2018 Jun 21;9:1436. doi: 10.3389/fimmu.2018.01436. eCollection 2018. Review.

8.

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.

Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J.

Sci Rep. 2018 Apr 24;8(1):6483. doi: 10.1038/s41598-018-24762-9.

9.

Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.

Fuerst TR, Pierce BG, Keck ZY, Foung SKH.

Front Microbiol. 2018 Jan 15;8:2692. doi: 10.3389/fmicb.2017.02692. eCollection 2017. Review.

10.

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.

Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P.

Antiviral Res. 2017 Dec;148:53-64. doi: 10.1016/j.antiviral.2017.10.015. Epub 2017 Oct 23.

11.

Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SKH.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E6946-E6954. doi: 10.1073/pnas.1614942113. Epub 2016 Oct 26.

12.

Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.

Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK.

Hepatology. 2016 Dec;64(6):1922-1933. doi: 10.1002/hep.28850. Epub 2016 Oct 28.

13.

Viral evasion and challenges of hepatitis C virus vaccine development.

Pierce BG, Keck ZY, Foung SK.

Curr Opin Virol. 2016 Oct;20:55-63. doi: 10.1016/j.coviro.2016.09.004. Epub 2016 Sep 19. Review.

14.

Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.

Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF.

Expert Rev Vaccines. 2016 Dec;15(12):1535-1544. Epub 2016 Jun 13. Review.

15.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.

16.

Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Keck ZY, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey FA, Krey T, Diamond MS, Foung SK.

J Virol. 2016 Jan 6;90(6):3112-22. doi: 10.1128/JVI.02458-15.

17.

Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, Aman MJ.

J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.

18.

Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.

Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK, Mariuzza RA.

J Biol Chem. 2015 Apr 17;290(16):10117-25. doi: 10.1074/jbc.M115.643528. Epub 2015 Mar 3.

19.

An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.

Zanin M, Keck ZY, Rainey GJ, Lam CY, Boon AC, Rubrum A, Darnell D, Wong SS, Griffin Y, Xia J, Webster RG, Webby R, Johnson S, Foung S.

J Virol. 2015 Apr;89(8):4549-61. doi: 10.1128/JVI.00078-15. Epub 2015 Feb 11.

20.

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Bailey JR, Wasilewski LN, Snider AE, El-Diwany R, Osburn WO, Keck Z, Foung SK, Ray SC.

J Clin Invest. 2015 Jan;125(1):437-47. doi: 10.1172/JCI78794. Epub 2014 Dec 15.

21.

Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.

Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH, Foung SK.

PLoS Pathog. 2014 Aug 14;10(8):e1004297. doi: 10.1371/journal.ppat.1004297. eCollection 2014 Aug.

22.

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.

Carlsen TH, Pedersen J, Prentoe JC, Giang E, Keck ZY, Mikkelsen LS, Law M, Foung SK, Bukh J.

Hepatology. 2014 Nov;60(5):1551-62. doi: 10.1002/hep.27298. Epub 2014 Oct 2.

23.

Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape.

Krey T, Meola A, Keck ZY, Damier-Piolle L, Foung SK, Rey FA.

PLoS Pathog. 2013;9(5):e1003364. doi: 10.1371/journal.ppat.1003364. Epub 2013 May 16.

24.

Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel AH, Bukh J, Foung SK.

J Virol. 2013 Jan;87(1):37-51. doi: 10.1128/JVI.01941-12. Epub 2012 Oct 24.

25.

Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.

Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH.

J Virol. 2012 Dec;86(23):12923-32. doi: 10.1128/JVI.02052-12. Epub 2012 Sep 19.

26.

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK.

PLoS Pathog. 2012;8(4):e1002653. doi: 10.1371/journal.ppat.1002653. Epub 2012 Apr 12.

27.

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SKH, Zeisel MB, Stoll-Keller F, Baumert TF.

Gastroenterology. 2012 Jul;143(1):223-233.e9. doi: 10.1053/j.gastro.2012.04.006. Epub 2012 Apr 10.

28.

Neutralizing antibody response to hepatitis C virus.

Wang Y, Keck ZY, Foung SK.

Viruses. 2011 Nov;3(11):2127-45. doi: 10.3390/v3112127. Epub 2011 Nov 2. Review.

29.

Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK.

J Biol Chem. 2011 Dec 23;286(51):44218-33. doi: 10.1074/jbc.M111.290783. Epub 2011 Oct 14.

30.

Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK.

J Virol. 2011 Oct;85(20):10451-63. doi: 10.1128/JVI.05259-11. Epub 2011 Aug 3.

31.

Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T.

J Virol. 2010 Jun;84(11):5751-63. doi: 10.1128/JVI.02200-09. Epub 2010 Mar 31.

32.

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK.

J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.

33.

CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.

Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH.

J Gen Virol. 2009 Jan;90(Pt 1):48-58. doi: 10.1099/vir.0.006700-0.

34.

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19450-5. doi: 10.1073/pnas.0809879105. Epub 2008 Dec 3.

35.

Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.

Machida K, Kondo Y, Huang JY, Chen YC, Cheng KT, Keck Z, Foung S, Dubuisson J, Sung VM, Lai MM.

J Virol. 2008 Jul;82(13):6711-20. doi: 10.1128/JVI.02582-07. Epub 2008 Apr 16.

36.

Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.

Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6061-6. doi: 10.1128/JVI.02475-07. Epub 2008 Apr 9.

37.

A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6067-72. doi: 10.1128/JVI.00252-08. Epub 2008 Apr 2.

38.

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SK, Ball JK, Patel AH.

J Gen Virol. 2008 Mar;89(Pt 3):653-9. doi: 10.1099/vir.0.83386-0.

39.

Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein.

Iacob RE, Keck Z, Olson O, Foung SK, Tomer KB.

Biochim Biophys Acta. 2008 Mar;1784(3):530-42. doi: 10.1016/j.bbapap.2007.12.015. Epub 2008 Jan 11.

40.

Antibody-dependent enhancement of hepatitis C virus infection.

Meyer K, Ait-Goughoulte M, Keck ZY, Foung S, Ray R.

J Virol. 2008 Mar;82(5):2140-9. Epub 2007 Dec 19.

41.

Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies.

Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK.

Curr Top Microbiol Immunol. 2008;317:1-38. Review.

PMID:
17990788
42.

The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.

Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C.

J Virol. 2007 Aug;81(15):8101-11. Epub 2007 May 23.

43.

Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Keck ZY, Xia J, Cai Z, Li TK, Owsianka AM, Patel AH, Luo G, Foung SK.

J Virol. 2007 Jan;81(2):1043-7. Epub 2006 Nov 1.

44.

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL.

J Biol Chem. 2006 Jul 7;281(27):18285-95. Epub 2006 May 4.

45.

Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.

Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z, Aviel S, Ilan E, Shoshany Y, Neville L, Waisman T, Ben-Moshe O, Kischitsky A, Foung SK, Keck ZY, Pappo O, Eid A, Jurim O, Zamir G, Galun E, Dagan S.

J Virol. 2006 Mar;80(6):2654-64.

46.

Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2.

Keck ZY, Li TK, Xia J, Bartosch B, Cosset FL, Dubuisson J, Foung SK.

J Virol. 2005 Nov;79(21):13199-208.

47.

Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide.

Taguchi H, Keck Z, Foung SK, Paul S, Nishiyama Y.

Bioorg Med Chem Lett. 2004 Sep 6;14(17):4529-32.

PMID:
15357986
48.

Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.

Keck ZY, Op De Beeck A, Hadlock KG, Xia J, Li TK, Dubuisson J, Foung SK.

J Virol. 2004 Sep;78(17):9224-32.

49.

Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.

Keck ZY, Sung VM, Perkins S, Rowe J, Paul S, Liang TJ, Lai MM, Foung SK.

J Virol. 2004 Jul;78(13):7257-63.

50.

Characterization of functional hepatitis C virus envelope glycoproteins.

Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J.

J Virol. 2004 Mar;78(6):2994-3002.

Supplemental Content

Support Center